N
25.83
2.36 (10.06%)
| Previous Close | 23.47 |
| Open | 23.53 |
| Volume | 291,054 |
| Avg. Volume (3M) | 151,978 |
| Market Cap | 368,643,584 |
| Price / Sales | 438.73 |
| Price / Book | 1.10 |
| 52 Weeks Range | |
| Earnings Date | 14 Nov 2025 |
| Operating Margin (TTM) | -9,701.19% |
| Diluted EPS (TTM) | -4.36 |
| Total Debt/Equity (MRQ) | 4.01% |
| Current Ratio (MRQ) | 21.03 |
| Operating Cash Flow (TTM) | -69.73 M |
| Levered Free Cash Flow (TTM) | -40.39 M |
| Return on Assets (TTM) | -21.97% |
| Return on Equity (TTM) | -34.96% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Neurogene Inc. | Bullish | Bearish |
AIStockmoo Score
1.5
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 1.50 |
|
Neurogene Inc is a clinical stage biotechnology company whose objective is to harness the power of gene therapy which is combined with its EXACT gene regulation technology to turn today’s complex devastating neurological diseases into treatable conditions. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 9.28% |
| % Held by Institutions | 115.82% |
| 52 Weeks Range | ||
| Median | 45.00 (74.22%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 09 Oct 2025 | 45.00 (74.22%) | Buy | 31.56 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 09 Oct 2025 | Announcement | Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Embolden™ Registrational Trial in Q4 2025 |
| 08 Oct 2025 | Announcement | Neurogene to Participate in H.C. Wainwright Genetic Medicines Virtual Conference |
| 03 Oct 2025 | Announcement | Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 05 Sep 2025 | Announcement | Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 11 Aug 2025 | Announcement | Neurogene Reports Second Quarter 2025 Financial Results and Highlights Recent Updates |
| 08 Aug 2025 | Announcement | Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |